Loading...
In utero exposure to anti–tumor necrosis factor (TNF) agents has not been associated with adverse neonatal health outcomes, but few studies have examined drug clearance and health effects during infancy.
In a prospective study, investigators measured maternal and fetal (via cord blood) levels of infliximab and adalimumab at the time of delivery in 80 pregnant women with inflammatory bowel disease (IBD) and continued to measure drug concentrations in infants with detectable levels at birth.
Cord blood levels at delivery were 21% higher than maternal blood levels for adalimumab and 97% higher for infliximab. The time between last drug administration to the mother and delivery was the only predictor of drug concentration in cord blood. Specifica…